Bluejay’s lead product candidate brelovitug (BJT-778) recently received U.S. Food and Drug Administration (FDA) Breakthrough Therapy designation for the treatment of chronic hepatitis delta (CHD).

Under the terms of the agreement, TG Therapeutics obtains non-exclusive research, clinical and commercial rights to use MaxCyte’s Flow Electroporation ® technology and ExPERT™ platform. In return, ...

India's new central bank chief Sanjay Malhotra is likely to take a growth-supportive approach over the next few months, as he ...

Sukhdev Singh is accused of fraudulently receiving approximately Rs 12 crore in compensation in collusion with some ...

WildBrain Ltd. ("WildBrain" or the "Company") (TSX: WILD), a global leader in kids' and family entertainment, today reported its second quarter ("Q2 2025") results for the period ended December 31, ...